Brief: Satsuma Pharmaceuticals Provides Sts101 Development Program And Corporate Update
20/12/2022 14:25
Dec 20 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O :
* SATSUMA PHARMACEUTICALS PROVIDES STS101 DEVELOPMENT
PROGRAM AND
CORPORATE UPDATE
* SSATSUMA IS WORKING TO SECURE A COMMERCIALIZATION PARTNER
FOR
STS101
* BELIEVES RESULTS OF ITS STS101 CLINICAL TRIAL PROGRAM
SUPPORT
PLANNED NDA FILING IN Q1 2023 AND POTENTIAL APPROVAL
* NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS OR
CARDIOVASCULAR
EVENTS OCCURRED
* STS101 DEMONSTRATED EFFICACY IN SUBJECTS WHO EXPERIENCED
COMMON
AND DIFFICULT-TO-TREAT MIGRAINE ATTACK TYPES
* STS101 DEMONSTRATED NUMERICAL BUT NOT STATISTICALLY
SIGNIFICANT
DIFFERENCES VERSUS PLACEBO ON STUDY CO-PRIMARY ENDPOINTS
Source text for Eikon: ID:nGNX9Zkz1F
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon